Health Catalyst, Inc.
HCATNASDAQHealthcare● Active
$1.75
$-0.19(-9.59%)
Market Cap$128945030
P/E Ratio—
52W High$4.291
52W Low$0.955
Health Catalyst, Inc. (HCAT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HCAT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$0.02
Est. $0.01 · +100.0%
Revenue
$0.07B
Est. $0.07B · +2.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
HCAT reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.02 | — | — | — | $0.07B | — |
| ▲ Q2 FY2026 | May 11, 2026 | $0.01 | $0.02 | +100.0% | $0.07B | $0.07B | +2.2% |
| ▼ Q1 FY2026 | Mar 12, 2026 | $0.09 | $0.08 | -11.1% | $0.07B | $0.07B | +1.0% |
| ▲ Q4 FY2025 | Nov 10, 2025 | $0.05 | $0.06 | +20.0% | $0.08B | $0.07B | +3.0% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.03 | $0.04 | +33.3% | $0.08B | $0.09B | -5.2% |
| — Q2 FY2025 | May 7, 2025 | $0.01 | $0.01 | +0.0% | $0.08B | $0.08B | +0.3% |
| ▼ Q1 FY2025 | Feb 26, 2025 | $0.11 | $0.04 | -63.6% | $0.08B | $0.08B | +0.0% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $0.10 | $0.07 | -30.0% | $0.08B | $0.08B | -5.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
$0.02
EPS Est.
$0.01
EPS Surpr.
+100.0%
Revenue
$0.07B
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
$0.08
EPS Est.
$0.09
EPS Surpr.
-11.1%
Revenue
$0.07B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
$0.06
EPS Est.
$0.05
EPS Surpr.
+20.0%
Revenue
$0.08B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.04
EPS Est.
$0.03
EPS Surpr.
+33.3%
Revenue
$0.08B
Q2 FY2025
May 7, 2025
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+0.0%
Revenue
$0.08B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
$0.04
EPS Est.
$0.11
EPS Surpr.
-63.6%
Revenue
$0.08B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$0.07
EPS Est.
$0.10
EPS Surpr.
-30.0%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2026 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q3 FY2026 | $-0.13 | $-0.00 | $0.31 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +100.0% | $1.52 | $1.38 | -9.21% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -11.1% | $1.86 | $1.79 | -3.76% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +20.0% | $2.83 | $2.85 | +0.71% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +33.3% | $3.82 | $3.69 | -3.40% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $4.07 | $3.97 | -2.46% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -63.6% | $4.95 | $4.94 | -0.20% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -30.0% | $7.76 | $8.25 | +6.31% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +33.3% | $5.93 | $5.48 | -7.59% |
Q2 FY2026-9.21%
Report Date
May 11, 2026
EPS Beat/Miss
+100.0%
Price Before
$1.52
Price After
$1.38
Q1 FY2026-3.76%
Report Date
Mar 12, 2026
EPS Beat/Miss
-11.1%
Price Before
$1.86
Price After
$1.79
Q4 FY2025+0.71%
Report Date
Nov 10, 2025
EPS Beat/Miss
+20.0%
Price Before
$2.83
Price After
$2.85
Q3 FY2025-3.40%
Report Date
Aug 7, 2025
EPS Beat/Miss
+33.3%
Price Before
$3.82
Price After
$3.69
Q2 FY2025-2.46%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$4.07
Price After
$3.97
Q1 FY2025-0.20%
Report Date
Feb 26, 2025
EPS Beat/Miss
-63.6%
Price Before
$4.95
Price After
$4.94
Q4 FY2024+6.31%
Report Date
Nov 6, 2024
EPS Beat/Miss
-30.0%
Price Before
$7.76
Price After
$8.25
Q3 FY2024-7.59%
Report Date
Aug 7, 2024
EPS Beat/Miss
+33.3%
Price Before
$5.93
Price After
$5.48
Avg Beat Reaction-4.39%
Avg Miss Reaction+0.78%
Beat Rate5 / 8 quarters
Largest Move-9.21% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HCAT ends December
Health Catalyst, Inc. (HCAT) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $0.02 — beating the analyst consensus of $0.01 by +100.0%. The next HCAT earnings date is expected around September 1, 2026.
Each quarter, investors track HCAT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HCAT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HCAT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HCAT earnings · 5 questionsHealth Catalyst, Inc.'s next earnings report is expected around September 1, 2026. HCAT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HCAT historically reports after market close (AMC).
HCAT earnings datewhen is HCAT earningsHCAT next earnings datewhen does HCAT report earningsHCAT earnings calendar
▸ Source: FMP · Health Catalyst, Inc. SEC filings · US GAAP · Health Catalyst, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026